Debate around infection-dependent hemophagocytic syndrome in paediatrics by unknown
DEBATE Open Access
Debate around infection-dependent
hemophagocytic syndrome in paediatrics
Valentina Ansuini1, Donato Rigante2 and Susanna Esposito1*
Abstract
Background: Hemophagocytic syndrome (HPS) is clinically defined as a combination of fever, liver dysfunction,
coagulation abnormalities, pancytopenia, progressive macrophage proliferation throughout the reticuloendothelial
system, and cytokine over-production, and may be primary or secondary to infectious, auto-immune, and tumoral
diseases. The most consistent association is with viral infections but, as it is still debated whether any
micro-organisms are involved in its pathogenesis, we critically appraised the literature concerning HPS and its
relationship with infections.
Discussion: Infection-dependent HPS has been widely observed, but there are no data concerning its incidence in
children. A better understanding of the pathophysiology of HPS may clarify the interactions between the immune
system and the variously implicated potential infectious agents. Epstein-Barr virus (EBV) infection has been
prominently associated with HPS, with clonal proliferation and the hyperactivation of EBV-infected T cells. However,
a number of other viral, bacterial, fungal, and parasitic infections have been reported in association with HPS. In the
case of low-risk HPS, corticosteroids and/or intravenous immunoglobulin or cyclosporine A may be sufficient to
control the biological process, but etoposide is recommended as a means of reversing infection-dependent
lymphohistiocytic dysregulation in high-risk cases.
Summary: HPS is a potential complication of various infections. A polymerase chain reaction search for infectious
agents including EBV, cytomegalovirus and Leishmania is recommended in clinical settings characterised by
non-remitting fever, organomegaly, cytopenia and hyperferritinemia.
Background
Hemophagocytic syndrome (HPS) is a potentially fatal
condition due to dysregulated lymphocyte activation and
proliferation, mainly characterised by impaired or inactive
natural killer (NK) cells and cytotoxic T cells, which leads
to macrophage hyperactivation and over-expression of
cytokines [1]. The result of this process is uncontrolled
and ineffective immune activation, multi-organ dysfunc-
tion, and hemophagocytosis throughout the reticuloen-
dothelial system [2]. The pathognomonic characteristic of
HPS is the activation of well-differentiated macrophages,
phagocyting erythrocytes, leukocytes and platelets in bone
marrow, lymph nodes, spleen, liver and other organs,
which can infiltrate almost anybody district and may
account for many of its systemic features [3]. HSP is still
often under-diagnosed and sub-optimally managed in chil-
dren [4], but the epidemiological data are fragmentary.
The syndrome was first described in 1939 as poorly-
controlled histiocyte proliferation, but has since also
been called hemophagocytic histiocytosis and macro-
phage activation syndrome [5-7]. It can be divided into a
primary genetic form and a secondary reactive form
(Table 1), a distinction that has historically been used to
differentiate cases of often fatal infantile HPS from those
caused by other etiologies that appear later in life and
have a better prognosis. This difference may be artifi-
cially scholastic because primary forms can occur at any
age (not only during infancy or early childhood) [8], and
both primary and secondary forms can be precipitated
by infections with a substantial risk of mortality [9].
Even secondary HPS occurs as an imbalance between in-
sufficient host defense, obstinate hyperinflammation,
and a heterogeneous triggering event, which can be of
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infectious, rheumatic or neoplastic nature: therefore, the
clinical disease results as the signature of a dysregulated
immune activation, leading to macrophage proliferation
and widespread hemophagocytosis in the reticuloen-
dothelial system. The aim of this review is to make a
critical appraisal of the literature concerning infection-
related HPS in paediatrics.
Discussion
A multi-face disease with variable causes
Genetic HPS is heterogeneous and arises from defects in
the critical regulatory pathways responsible for the natural
termination of immune responses that lead to the failure
of the homeostatic removal of cells that are superfluous or
dangerous to the host. Since 1999, various genetic loci
related to the activity of perforin and granzyme granules
have been associated with genetic autosomal recessive
HPS, thus explaining the impaired or absent function of
NK cells and cytotoxic T cells [2,6]. The familial form,
which was first described in 1952 [10], is an autosomal re-
cessive disorder that is estimated to occur in 1/30,000-
50,000 births, and usually appears during the first year of
life [11,12]. Sporadic cases of HPS associated with mul-
tiple genetic mutations have also been described [13].
The different primary forms of HPS are associated with
immune deficiencies, including Chediak-Higashi syn-
drome, Griscelli syndrome, X-linked lymphoproliferative
syndrome, Wiskott-Aldrich syndrome, severe combined
immunodeficiency, lysinuric protein intolerance, and
Hermansky-Pudlak syndrome. Acquired HPS has also
been associated with a variety of viral, bacterial and
mycobacterial, fungal, and parasitic infections [14], auto-
immune diseases [15], auto-inflammatory syndromes
[16], and tumours, particularly T cell malignancies [17].
The constellation of signs and symptoms of HPS is not
specific and none of the biochemical abnormalities is dis-
tinctive. The dramatic presentation of the syndrome
includes unremitting fever, visceromegaly, thrombocyto-
penia, lethargy, seizures, skin rash, pulmonary failure, and
cardiac and/or renal involvement, and the mortality rate is
8-22% [18]. The most common laboratory findings are
due to liver dysfunction, and include low fibrinogen, and
high serum triglycerides and ferritin levels [18]. Two
highly diagnostic clues are increased plasma concentra-
tions of the alpha chain of interleukin-2 receptors (also
known as sCD25) and impaired NK cell activity. As treat-
ment can be life-saving and some of the clinical criteria
occur late during the course of the disease, it is not neces-
sary to satisfy all of the criteria before beginning therapy.
The hallmark of HPS is the phagocytosis of blood cells
and their precursors: bone marrow aspiration typically
reveals the normal maturity of all cell lineages, and infil-
tration by activated macrophages “stuffed” with other
blood cells [19].
Criteria for a diagnosis of HPS on the basis of clinical,
laboratory, and histopatological findings are the follow-
ing [3]:
(1) Genetic diagnosis: genes known to cause the syndrome
(PRF1, UNC13D, STX11, STXBP2, RAB27A)




c) cytopenias (minimum 2 cell lines reduced)
d) hypertriglyceridemia (≥ 265 mg/dL) and/or
hypofibrinogenemia (≤ 150 g/dL)
e) hemophagocytosis in any involved organ
f ) very little or no NK cell activity
g) increased ferritin ≥ 500 mg/L
h) increased soluble CD25 (serum interleukin-2
receptor alpha) ≥ 2.400 U/mL
The main pathophysiological abnormality in HPS is cyto-
kine dysfunction, which leads to the uncontrolled accumu-
lation and ectopic migration of activated T lymphocytes,
antigen-presenting cells and histiocytes, and multi-system
inflammation [20]. The pathophysiology of acquired HPS
has not been fully defined, but deficient cytolytic activity
leads to the persistent activation of lymphocytes and histio-
cytes, followed by the hypersecretion of pro-inflamatory
cytokines and high soluble interleukin-2 receptor levels
that correlate with the prognosis [21].
Table 1 Classification of hemophagocytic syndrome
Type of hemophagocytic syndrome Subtype
Primary or genetic hemophagocytic
syndrome
Familial hemophagocytic lymphohistiocytosis
Immune deficiency syndromes (i.e., Chediak-Higashi syndrome, Griscelli syndrome, X-linked
lymphoproliferative syndrome)
Secondary or reactive hemophagocytic
syndrome
Infections (i.e., viral, bacterial, parasitic)
Malignancies
Auto-immune and auto-inflammatory diseases
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Infectious etiologies of HPS
The association between HPS and infections has been
widely documented and both familial or sporadic cases
are often precipitated by acute infections. It must also be
pointed out that every form of HPS can mimic infectious
diseases or overwhelming bacterial sepsis, thus hindering
the diagnosis of a precipitating and treatable infectious
illness. Virus-associated HPS was first described in 1979
by Risdall et al., whose series consisted of 19 patients,
most of whom were immunocompromised but without
any confirmed genetic or acquired immunodeficiency,
and all of whom showed serological signs of viral infec-
tion [22,23]. Since then, there have been reports of HPS
associated with a host of infections [22].
HPS associated with viral infections
Epstein-Barr virus (EBV) is the most commonly reported
trigger of HPS [24]. The epidemiology of EBV-related HPS
is not well known, although a higher incidence has been
observed in Asian countries, where it has been theorised
there may be a more pathogenic viral strain that is genet-
ically similar to the strains observed in nasopharyngeal
carcinoma cell lines [25]. Two forms of EBV-related HPS
have been described: the first occurring during primary in-
fection and the second during a reactivation process [26].
During primary infection, EBV typically infects and repli-
cates in B cells, whereas EBV-specific cytotoxic T cells are
required to produce memory cells. In rare cases, EBV may
infect T and NK cells and induce persistent EBV infection,
which may lead to chronic active EBV infection, lympho-
proliferative disorders and fulminant EBV-related HPS
[27-29]. Serological testing can help determine whether
EBV-associated HPS has occurred in the setting of acute
infection or is the result of a reactivation process. In
addition, the real-time polymerase chain reaction (PCR)
detection and quantification of EBV nucleic acid is an im-
portant laboratory means of adequately reflecting viral
replication and assessing EBV load in patients with EBV-
related HPS [30]. The quantitative analysis of cell-free
EBV genome copy numbers after four months of treat-
ment can assess therapeutic responses and is prognostic-
ally significant [31].
The clonal expansion of EBV-infected T lymphocytes
has been demonstrated in EBV-related HPS [32] and EBV-
positive T cell lymphoma [33] on the basis of the presence
of homogeneous viral terminal repeat sequences. The
clonality of infected T lymphocytes is further suggested by
the finding of monoclonal rearrangements of the T cell
receptor-alpha gene in EBV-related HPS [34]. The distinc-
tion between the monoclonal proliferation of T lympho-
cytes seen in EBV-related HPS and EBV-positive T cell
lymphomas may describe the extremes of a spectrum of
disordered T lymphocyte proliferation following EBV in-
fection. The inflammatory cytokine over-production seen
in patients with EBV-related HPS tends to be much more
pronounced than that observed in patients with other
forms of HPS [35]. Of all of the infections associated with
HPS, EBV infection has the worst prognosis in the pres-
ence of underlying hereditary disorders, diffuse intravascu-
lar coagulation, neutropenia, or central nervous system
involvement [36].
Treatment strategies vary significantly depending on
the clinical features of the infection: mild cases of EBV-
related HPS are treated conservatively as spontaneous
regression has been reported, and antiviral therapy with
acyclovir, ganciclovir or cidofovir has led to disappoint-
ing results [37]. In the case of severe EBV-related HPS,
the introduction of immuno-chemotherapy and, if neces-
sary, allogenic stem cell transplantation has radically chan-
ged the history and prognosis of the disease: in such cases,
the optimal treatment strategy can be centred on im-
munosuppressive medications that inhibit overactive T
and NK cell responses (i.e. corticosteroids, cyclosporine A,
intravenous immunoglobulin, anti-thymocyte globulins,
etoposide, rituximab, and plasma or blood exchange trans-
fusions) [38,39]. Hematopoietic stem cell transplantation
is the last treatment resort for refractory forms of EBV-
related HPS, and in the case of EBV infection occurring in
genetic forms of HPS [40].
The most frequent herpes viruses associated with HPS
other than EBV are cytomegalovirus (CMV) and human
herpes virus 8 (HHV8).
CMV up-regulates tumour necrosis factor gene expres-
sion and has been associated with HPS in otherwise
healthy patients, patients with inflammatory bowel dis-
ease, rheumatological diseases and cancer, and transplant
recipients [41]. HPS was observed in seven of a series of
171 patients undergoing hematopoietic stem cell trans-
plantation, and was triggered by CMV in three cases [42].
Younger age may be associated with a worse prognosis
[43]. A recent study has shown that the use of specific
anti-CMV therapy, such as CMV immunoglobulin, foscar-
net or ganciclovir, may be therapeutic [44].
HHV8 has been associated with HPS in 13 patients: most
of these cases occurred in patients with a lymphoprolifera-
tive disorder [45] or immunocompromised patients [46],
and rarely in immunocompetent hosts [47]. Treatment
based on etoposide, ganciclovir, foscarnet or rituximab has
led o successful results [48].
HPS can be associated with human immunodeficiency
virus (HIV) infection, alone or with a wide variety of
underlying disorders. It is likely that this condition is
underestimated as HIV infection and HPS have many
clinical and laboratory similarities. About 10% of bone
marrow biopsies taken from HIV patients before the
start of highly active antiretroviral therapy show active
signs of hemophagocytosis [49]. HIV-related HPS can be
observed in cases of acute or late HIV infection, and in
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conjunction with immune reconstitution inflammatory
syndrome, opportunistic infections, or malignancies [50].
HPS may even be the initial presentation of HIV infec-
tion [51], and it has been suggested that HIV itself may
play a direct role in triggering the syndrome [52]. Other
common viral triggers of HPS in HIV patients are EBV,
CMV and HHV8, and EBV-related HPS seems to be
more frequent in HIV-infected children [53].
Influenza-related HPS has been rarely reported in im-
munocompromised and otherwise healthy children [54-57].
One fatal case of HPS was observed among 32 children
hospitalised with seasonal influenza in a prospective
pediatric study [58], but reactive HPS has also been asso-
ciated with avian and swine (non-pandemic) influenza
[59,60]. In particular, patients with severe H5N1 (avian)
influenza infection have symptoms and laboratory findings
that are similar to those observed in patients with HPS,
mainly encephalitis, organ dysfunction with hemophago-
cytosis, bone marrow failure, and pro-inflammatory cyto-
kine over-production [61]. Clinical studies have found that
mutations in some viral genes (NS1, PB2, HA and NA)
are significantly related to cytokine release, and it has been
demonstrated that recombinant hemagglutinin (H5) from
H5N1 virus can suppress perforin expression and reduce
the cytotoxicity of T cells, including their ability to kill
H5-bearing cells [62]. Some authors have suggested treat-
ment with a shorter course of etoposide and dexametha-
sone [63].
HPS has been reported in 28 cases of parvovirus B19
infection, most of whom had hereditary spherocytosis as
the underlying disease: fewer than half were children
[64-68]. Of these patients, 16 did not receive any treat-
ment and 22 survived, thus suggesting that the prognosis
of parvovirus-associated HPS is better than that of the
other viral-mediated forms of HPS.
Fulminant viral hepatitis may mimic and even cause
HPS, with hepatitis A virus being more frequently asso-
ciated with HPS than the other hepatotrope viruses.
Fifteen cases (including children) have been described,
mainly in Asia: three of these patients also had a concur-
rent rheumatological disease (systemic juvenile idiopathic
arthritis or Still’s disease) and two also had hepatitis C.
Their treatment consisted of corticosteroids, variously
combined with intravenous immunoglobulin, but four
patients received no specific treatment and 11 of the 15
experienced a favourable outcome [69-71].
Enterovirus-related HPS has been described in 12
pediatric cases: five occurred in infants aged <1 year, and
the oldest patient was 18 years old. An underlying dis-
ease was found in four patients who experienced a fatal
outcome (lymphoid neoplasms, lymphoblastic leukemia
and juvenile idiopathic arthritis). Ten patients received
intravenous immunoglobulin (six in combination with
corticosteroids), but only seven patients survived [72].
Other viruses associated with HPS include adenovirus,
paramyxovirus (leading to measles and mumps), rubella
virus, human parainfluenza viruses, Flavivirus (leading
to dengue fever) and hantavirus (leading to hemorrhagic
fever and severe acute respiratory syndrome), all of
which have been treated with varying courses of corti-
costeroids and intravenous immunoglobulin.
HPS associated with bacterial infections
Reactive HPS has frequently been associated with intra-
cellular pathogens. The pathophysiology of HPS asso-
ciated with non-viral agents may be related to the
production of high levels of activating cytokines by host
lymphocytes and monocytes. Although the pathophysio-
logical response of the host immune system to the infec-
tious agent is not fully understood, it is hypothesised
that functional deficiencies in NK and cytoxic T cells
may occur during the illness [73].
HPS can be associated with disseminatedMycobacterium
tuberculosis infection. Thirty-six cases (including infants
and children) have so far been reported, approximately
half of which were accompanied by comorbidities: eight
patients had end-stage renal disease and were receiving
hemodialysis or had undergone renal transplantation, four
had a history of a malignancy, two had AIDS, and one had
sarcoidosis. Fever was the most frequent clinical feature
upon presentation, combined with visceromegaly and
pancytopenia, and all of the patients underwent bone
marrow aspirations that confirmed hemophagocytosis.
Evidence of extra-pulmonary tuberculosis was found in
83% of cases. The concluding remarks of the report sta-
ted that tuberculosis-related HPS has a poor prognosis,
with a mortality rate of approximately 50%, although
anti-tuberculous and immunomodulatory therapy (con-
sisting of high-dose corticosteroids, intravenous im-
munoglobulin, anti-thymocyte globulin, cyclosporine A,
epipodophyllotoxin or plasma exchange) may lead to a
better outcome [74]. Early diagnostic confirmation and
the timely administration of anti-tuberculous medication
seem to be crucial in these patients. One reported case of
HPS occurred after childhood vaccination with the bacil-
lus Calmette-Guérin [75].
HPS has also been described in association with bru-
cellosis, with Brucella melitensis being the most fre-
quently isolated organism [76]. Leptospirosis can cause
life-threatening HPS as a result of an insufficient or
misdirected immunological response to Leptospira it-
self: antibiotic treatment alone is not sufficient in such
cases, and treatment with corticosteroids, intravenous
immunoglobulin or etoposide is required [77]. Rickett-
sial diseases, transmitted to humans by arthropod bites
and usually controlled at an intracellular level by nitric
oxide synthesis, hydrogen peroxide production, and
tryptophan degradation have also been related to HPS:
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overall, 15 cases of rickettsial disease confirmed sero-
logically and complicated by HPS have been published
in the period 1990–2010, with only 3 cases occurring in
patients less than 15 years and a prognosis influenced by
the specific Rickettsia species, patient’s immunologic
equipment, and delay in antibiotic therapy or corticoster-
oid therapy [78]. In 2009, sepsis caused by multidrug-
resistant Acinetobacter baumannii following urinary tract
infection was reported for the first time in a previously
healthy 3-year-old child, who recovered after multiple
doses of granulocyte colony stimulating factor and red
blood cell/platelet transfusions without any cytotoxic
treatment or immunotherapy [79].
HPS associated with parasitic and fungal infections
HPS can be associated with Leishmania donovani and
Leishmania infantum infections, but leishmaniasis may
also mimic the syndrome, as it is characteristically asso-
ciated with organomegaly and pancytopenia. This is par-
ticularly important in non-endemic areas, where visceral
leishmaniasis is unlikely to be included in the differential
diagnosis, and repeated bone marrow smears are often
required to identify Leishmania species by means of PCR
with species-specific probes [80]. Specific anti-leishmania
treatment with amphotericin B is usually sufficient to con-
trol HPS. Unfortunately, sporadic cases of undiagnosed
leishmaniasis have been treated as HPS with fatal conse-
quences [81].
Malaria (caused by Plasmodium falciparum and Plas-
modium vivax), toxoplasmosis, babesiosis, and strongyl-
oidiasis have been rarely identified in association with
HPS: a history of travel from endemic countries may help
to identify these triggering agents [82].
Yeast (Candida spp., Cryptococcus spp. and Pneumocystis
spp.) and moulds (Histoplasma spp., Aspergillus spp. and
Fusarium spp.) have been associated with the occurrence
of HPS, most commonly during HIV infection, neoplastic
diseases, protracted corticosteroid administration, and
transplantation [83-85].
Disseminated Penicillium marneffei infection is com-
mon among HIV-infected patients in many regions in
Southeast Asia: the first case of HPS associated with
penicilliosis in a Thai HIV-infected child was reported in
2001, with complete recovery after antifungal and intra-
venous immunoglobulin therapy [86].
Conclusions
Many immunological, neoplastic and genetic disorders
may underlie HPS, but infectious causes are the most
prevalent and most frequently reported in association
with this syndrome.
The specific clinical and laboratory tests for microbio-
logical identification of HPS are the following:
(1) Blood, mid-stream urine, cerebrospinal fluid and
sputum cultures for bacteria and fungi; cultures/
microscopy for mycobacteria; tuberculin skin test
and/or interferon-release tests
(2) Bone marrow aspirate
(3) Serological tests for acute Epstein-Barr,
cytomegalovirus and human immunodeficiency
virus infections
(4) Peripheral blood nucleic acid tests for evidence of
replicating Epstein-Barr virus, cytomegalovirus,
herpes simplex virus, human herpes virus-8, human
immunodeficiency virus, adenovirus and parvovirus
B19
(5) Serological tests for evidence of primary
toxoplasmosis or reactivation
(6) Leishmania antigen test
(7) Serum cryptococcal antigen and serum
galactomannans
As a fatal outcome may occur when infection-related
HPS is only treated supportively, a multidisciplinary ap-
proach by experienced clinicians and infectious disease
specialists is required in order to ensure the appropriate
management of the syndrome itself, and the precipitat-
ing or underlying infection. Pediatricians should be alert
and aware of the risk of the syndrome, because an early
diagnosis can change its natural history and it has been
shown that prompt treatment improves the overall
prognosis. A combination of high fever unresponsive to
broad-spectrum antibiotics, hyperferritinemia, hypertrigly-
ceridemia, hypofibrinogenemia, cytopenia, organomegaly
and characteristic histological findings in the setting of an
infectious process (particularly EBV infection, but also
other viral and bacterial, parasitic and fungal infections) is
the key diagnostic clue. A better understanding of the
pathophysiology of HPS should clarify the interactions be-
tween immune system pathways and infections. Specific
antimicrobial therapy can be beneficial in selected cases,
whereas antiviral drugs do not seem to be curative. Severe
cases of infection-dependent HPS require immunosup-
pressants or chemotherapeutic agents, while bone marrow
transplantation is the ultimate choice for persistent refrac-
tory cases.
Summary
Hemophagocytic syndrome (HPS) can occur as a rare
complication of various infections in children. Clonal pro-
liferation of T lymphocytes with an excessive activation of
macrophages can be triggered by different infectious
agents, thus indicating that infection per se is involved in
the pathogenetic mechanism of the process. A number of
studies have demonstrated that HPS is frequently trig-
gered by one of many different viral, bacterial, parasitic
or fungal infections, with large differences in terms of
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treatment responses and overall outcomes. All patients
meeting the criteria for HPS should undergo initial tests
to diagnose the underlying infecting organism, which
should be guided by epidemiological data and the patient’s
medical history. A polymerase chain reaction search for
infectious agents, including EBV, CMV and Leishmania, is
recommended in a clinical scenario characterised by unre-
mitting fever, organomegaly, cytopenia and hyperferritine-
mia. As HPS may be associated with many infectious
diseases and immunological, neoplastic or genetic disor-
ders, the close cooperation of pediatricians and infectious
disease specialists is crucial in order to define any precipi-
tating or underlying condition.
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